Trial Profile
Phase I/II Open-Label Safety and Dose Finding Study of Adeno-Associated Virus (AAV) rh10-Mediated Gene Transfer of Human Factor IX in Adults With Moderate/Severe to Severe Hemophilia B
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs DTX 101 (Primary)
- Indications Haemophilia B
- Focus Adverse reactions; First in man
- Sponsors Dimension Therapeutics
- 12 Dec 2017 Results presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 12 Dec 2017 Results assessing Immune responses, presented at the 59th Annual Meeting and Exposition of the American Society of Hematology
- 10 May 2017 According to a Dimension Therapeutics media release, the company announced its decision to discontinue the development of DTX101 for the treatment of moderate/severe-to-severe hemophilia B based on the analysis of the data from this and other (CTP-260780) study which revealed it would not meet the company's minimum target product profile for continued development or future commercialization.